JP2007513633A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007513633A5 JP2007513633A5 JP2006544092A JP2006544092A JP2007513633A5 JP 2007513633 A5 JP2007513633 A5 JP 2007513633A5 JP 2006544092 A JP2006544092 A JP 2006544092A JP 2006544092 A JP2006544092 A JP 2006544092A JP 2007513633 A5 JP2007513633 A5 JP 2007513633A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- 210000004602 germ cell Anatomy 0.000 description 9
- 238000009795 derivation Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 1
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- IFLVGRRVGPXYON-UHFFFAOYSA-N adci Chemical compound C12=CC=CC=C2C2(C(=O)N)C3=CC=CC=C3CC1N2 IFLVGRRVGPXYON-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52875703P | 2003-12-10 | 2003-12-10 | |
| US60/528,757 | 2003-12-10 | ||
| PCT/US2004/041777 WO2005059106A2 (en) | 2003-12-10 | 2004-12-10 | Interferon alpha antibodies and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010267571A Division JP2011097943A (ja) | 2003-12-10 | 2010-11-30 | インターフェロンα抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007513633A JP2007513633A (ja) | 2007-05-31 |
| JP2007513633A5 true JP2007513633A5 (enExample) | 2009-09-10 |
| JP5047626B2 JP5047626B2 (ja) | 2012-10-10 |
Family
ID=34699898
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006544092A Expired - Fee Related JP5047626B2 (ja) | 2003-12-10 | 2004-12-10 | インターフェロンα抗体及びその使用 |
| JP2010267571A Pending JP2011097943A (ja) | 2003-12-10 | 2010-11-30 | インターフェロンα抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010267571A Pending JP2011097943A (ja) | 2003-12-10 | 2010-11-30 | インターフェロンα抗体及びその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US7741449B2 (enExample) |
| EP (2) | EP1711207B1 (enExample) |
| JP (2) | JP5047626B2 (enExample) |
| KR (2) | KR101225299B1 (enExample) |
| CN (2) | CN1889978A (enExample) |
| AU (2) | AU2004299833B2 (enExample) |
| CA (1) | CA2546054C (enExample) |
| DK (2) | DK1711207T3 (enExample) |
| ES (2) | ES2641831T3 (enExample) |
| HU (1) | HUE035520T2 (enExample) |
| IL (1) | IL175586A (enExample) |
| IN (1) | IN2009KN02655A (enExample) |
| LT (1) | LT2418220T (enExample) |
| NZ (1) | NZ547157A (enExample) |
| PL (2) | PL2418220T3 (enExample) |
| PT (2) | PT2418220T (enExample) |
| SI (2) | SI2418220T1 (enExample) |
| WO (1) | WO2005059106A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8188249B2 (en) | 2003-09-10 | 2012-05-29 | Amgen Fremont Inc. | Nucleic acid molecules encoding antibodies to M-CSF |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2236156A3 (en) * | 2001-01-09 | 2011-01-05 | Baylor Research Institute | Methods for treating and diagnosing Psoriasis |
| EP1631312B1 (en) * | 2003-04-23 | 2008-09-10 | Medarex, Inc. | Compositions and methods for the therapy of inflammatory bowel disease |
| DK1711207T3 (da) | 2003-12-10 | 2013-03-11 | Medarex Inc | Interferon-alpha-antistoffer og anvendelse heraf |
| EP1781705B1 (en) | 2004-06-21 | 2014-10-08 | Medarex, L.L.C. | Interferon alpha receptor i antibodies and their uses |
| NZ554065A (en) * | 2004-10-07 | 2010-12-24 | Univ Zuerich | Use of an anti-interferon-alpha antibody for prevention and treatment of psoriasis |
| CA2597265C (en) | 2005-02-10 | 2015-03-24 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| US7888481B2 (en) * | 2005-02-10 | 2011-02-15 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| WO2007002543A2 (en) | 2005-06-23 | 2007-01-04 | Medimmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
| CA2630483C (en) | 2005-12-08 | 2015-05-19 | Medarex, Inc. | Human monoclonal antibodies to o8e |
| EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| JP5784272B2 (ja) * | 2006-04-24 | 2015-09-24 | ジェネンテック， インコーポレイテッド | 自己免疫性疾患を検出するための方法及び組成物 |
| WO2008048545A2 (en) | 2006-10-16 | 2008-04-24 | Medimmune, Llc. | Molecules with reduced half-lives, compositions and uses thereof |
| CN101678100A (zh) | 2006-12-06 | 2010-03-24 | 米迪缪尼有限公司 | 治疗系统性红斑狼疮的方法 |
| WO2008070135A2 (en) * | 2006-12-06 | 2008-06-12 | Medimmune, Llc. | Methods of treating systemic lupus erythematosus |
| AU2008232903B9 (en) * | 2007-03-30 | 2013-09-05 | Medimmune Llc | Antibodies with decreased deamidation profiles |
| CA2685147A1 (en) * | 2007-05-03 | 2008-11-13 | Medimmune, Llc | Auto-antibody markers of autoimmune disease |
| US20100261172A1 (en) * | 2007-05-03 | 2010-10-14 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
| DK3072525T3 (en) | 2007-05-14 | 2018-04-30 | Astrazeneca Ab | PROCEDURES FOR REDUCING BASOFILE CELL LEVELS |
| ES2687808T3 (es) | 2007-09-26 | 2018-10-29 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| CN101909444B (zh) | 2007-11-05 | 2013-09-18 | 米迪缪尼有限公司 | 硬皮病治疗方法 |
| US9308257B2 (en) * | 2007-11-28 | 2016-04-12 | Medimmune, Llc | Protein formulation |
| TW200938224A (en) * | 2007-11-30 | 2009-09-16 | Medarex Inc | Anti-B7H4 monoclonal antibody-drug conjugate and methods of use |
| EP2272872A4 (en) * | 2008-03-21 | 2011-04-06 | Hayashibara Biochem Lab | MONOCLONAL ANTIBODY SPECIFICALLY RECOGNIZING HUMAN INTERFERON ALPHA FROM THE SUB-TYPE ALPHA-8 AND MUTATED PROTEIN THEREOF |
| EP2279207B1 (en) | 2008-05-07 | 2015-09-09 | Argos Therapeutics, Inc. | Humanized antibodies against human interferon-alpha |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| WO2010042705A1 (en) * | 2008-10-09 | 2010-04-15 | Medimmune, Llc | Antibody formulation |
| WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
| TWI646193B (zh) | 2009-03-19 | 2019-01-01 | 中外製藥股份有限公司 | 抗體恆定區域改變體 |
| KR101844859B1 (ko) * | 2009-08-06 | 2018-05-18 | 제넨테크, 인크. | 단백질 정제 시의 바이러스 제거의 개선방법 |
| ES2613055T3 (es) | 2009-09-03 | 2017-05-22 | Medimmune, Llc | Diagnóstico de interferón de tipo 1 |
| JP5837821B2 (ja) | 2009-09-24 | 2015-12-24 | 中外製薬株式会社 | 抗体定常領域改変体 |
| EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| GB201012784D0 (en) * | 2010-07-29 | 2010-09-15 | Ucb Pharma Sa | Method |
| JP5986570B2 (ja) | 2010-09-01 | 2016-09-06 | トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 筋修復および再生のための組成物および方法 |
| TR201802772T4 (tr) | 2010-11-17 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül. |
| EP3604330A1 (en) | 2011-02-25 | 2020-02-05 | Chugai Seiyaku Kabushiki Kaisha | Fcgammariib-specific fc antibody |
| RU2013157177A (ru) * | 2011-05-25 | 2015-06-27 | МЕДИММЬЮН, ЭлЭлСи | Способы лечения системной красной волчанки, склеродермии и миозита |
| MX340498B (es) | 2011-06-30 | 2016-07-11 | Chugai Pharmaceutical Co Ltd | Polipeptido heterodimerizado. |
| AU2012316859A1 (en) | 2011-09-29 | 2014-04-17 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
| EP2762493B1 (en) | 2011-09-30 | 2021-06-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| TW201326209A (zh) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| BR112014013081A2 (pt) | 2011-11-30 | 2020-10-20 | Chugai Seiyaku Kabushiki Kaisha | veículo contendo fármaco em célula para formação de um complexo imune |
| WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
| EP2802356A1 (en) * | 2012-01-13 | 2014-11-19 | Apo-T B.V. | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
| SG11201404751UA (en) | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| EP4310191A3 (en) | 2012-06-14 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing modified fc region |
| AR091649A1 (es) * | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| CN105102618B (zh) | 2012-12-27 | 2018-04-17 | 中外制药株式会社 | 异源二聚化多肽 |
| CN105358575B (zh) * | 2013-03-15 | 2020-09-22 | 詹森生物科技公司 | 干扰素α和ω抗体拮抗剂 |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| EP4056591A1 (en) * | 2013-07-03 | 2022-09-14 | ImmunoQure AG | Human anti-ifn-alpha antibodies |
| US10081681B2 (en) | 2013-09-20 | 2018-09-25 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
| ES2881306T3 (es) | 2013-09-27 | 2021-11-29 | Chugai Pharmaceutical Co Ltd | Método para la producción de heteromultímeros de polipéptidos |
| TWI713453B (zh) * | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| KR101655567B1 (ko) | 2014-11-10 | 2016-09-07 | 현대자동차주식회사 | 하이브리드 차량의 구동 제어 장치 |
| HUE056489T2 (hu) | 2014-12-19 | 2022-02-28 | Chugai Pharmaceutical Co Ltd | Anti-C5 antitestek és alkalmazási eljárások |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| WO2016112497A1 (zh) * | 2015-01-13 | 2016-07-21 | 中国人民解放军军事医学科学院生物工程研究所 | 人源抗人α干扰素抗体及其应用 |
| SG11201706014PA (en) | 2015-02-05 | 2017-08-30 | Chugai Pharmaceutical Co Ltd | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| SG11201705093UA (en) | 2015-02-27 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Composition for treating il-6-related diseases |
| WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| US10222547B2 (en) | 2015-11-30 | 2019-03-05 | Corning Incorporated | Flame-retardant optical fiber coating |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| JP7219005B2 (ja) | 2015-12-28 | 2023-02-07 | 中外製薬株式会社 | Ｆｃ領域含有ポリペプチドの精製を効率化するための方法 |
| EP3431102A4 (en) | 2016-03-14 | 2019-09-25 | Chugai Seiyaku Kabushiki Kaisha | CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY |
| JP7320943B2 (ja) | 2016-04-28 | 2023-08-04 | 中外製薬株式会社 | 抗体含有製剤 |
| KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| US10167396B2 (en) | 2017-05-03 | 2019-01-01 | Corning Incorporated | Low smoke fire-resistant optical ribbon |
| BR112019021847A2 (pt) | 2017-05-30 | 2020-06-02 | Bristol-Myers Squibb Company | Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1 |
| HUE065242T2 (hu) | 2017-05-30 | 2024-05-28 | Bristol Myers Squibb Co | LAG-3-pozitív tumorok kezelése |
| CA3069105A1 (en) | 2017-07-03 | 2019-01-10 | Torque Therapeutics, Inc. | Polynucleotides encoding immunostimulatory fusion molecules and uses thereof |
| AU2018361430B2 (en) | 2017-11-01 | 2025-08-14 | Chugai Seiyaku Kabushiki Kaisha | Antibody variant and isoform with lowered biological activity |
| EP4640703A2 (en) | 2017-11-14 | 2025-10-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibodies and methods of use |
| AU2019249427A1 (en) | 2018-04-02 | 2020-10-29 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| UA130009C2 (uk) | 2018-05-07 | 2025-10-15 | Генмаб А/С | Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу |
| EP3835321A4 (en) | 2018-08-10 | 2022-11-02 | Chugai Seiyaku Kabushiki Kaisha | ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF |
| CN109053892B (zh) | 2018-09-19 | 2021-03-26 | 苏州思坦维生物技术股份有限公司 | 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| US12187794B2 (en) * | 2019-02-04 | 2025-01-07 | Alamab Therapeutics, Inc. | Connexin 43 antibodies and use thereof |
| JP2022527542A (ja) | 2019-04-04 | 2022-06-02 | ヤンセン バイオテツク，インコーポレーテツド | 抗ＩＦＮ－α／ω抗体の投与方法 |
| CA3136602A1 (en) | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
| BR112021021689A2 (pt) | 2019-05-15 | 2022-03-22 | Chugai Pharmaceutical Co Ltd | Molécula de ligação a antígeno, composição farmacêutica, e método |
| AU2020358101A1 (en) | 2019-10-02 | 2022-04-28 | Alamab Therapeutics, Inc. | Anto-connexin antibody formulations |
| US20240327529A1 (en) | 2020-11-18 | 2024-10-03 | Astrazeneca Ab | Steroid sparing |
| LT4114465T (lt) | 2021-04-23 | 2023-11-10 | Astrazeneca Ab | Anti-ifnar1 dozavimo režimas, skirtas poodinei injekcijai |
| EP4377349A1 (en) | 2021-07-27 | 2024-06-05 | Astrazeneca AB | Treatment of lupus |
| US20250163163A1 (en) * | 2021-12-22 | 2025-05-22 | Chugai Seiyaku Kabushiki Kaisha | Antibody variant with reduced biological activity |
| JP2023159309A (ja) * | 2021-12-22 | 2023-10-31 | 中外製薬株式会社 | 生物活性が低下した抗体バリアント |
| CN121127499A (zh) | 2023-05-19 | 2025-12-12 | 阿斯利康(瑞典)有限公司 | 狼疮的治疗 |
| WO2025022280A1 (en) | 2023-07-21 | 2025-01-30 | Astrazeneca Ab | Treatment of neurodegenerative diseases |
| GB202315831D0 (en) | 2023-10-16 | 2023-11-29 | Astrazeneca Ab | Treatment of skin disease |
| WO2025084911A1 (ko) * | 2023-10-17 | 2025-04-24 | 한양대학교 산학협력단 | 간 줄기세포에 대한 단일클론항체 및 이의 용도 |
| WO2025147586A1 (en) * | 2024-01-05 | 2025-07-10 | Agilent Technologies, Inc. | Controlling antibody specificities in a polyclonal humoral response by epitope tuning |
| GB202402824D0 (en) | 2024-02-28 | 2024-04-10 | Astrazeneca Ab | Treatment of chronic kidney disease |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4423147A (en) * | 1980-04-11 | 1983-12-27 | Secher David S | Monoclonal antibody to interferon-α |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| EP0139676B1 (en) * | 1983-02-04 | 1992-11-25 | Cytoclonal Pharmaceutics Inc. | Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| FR2560212B1 (fr) * | 1984-02-24 | 1989-12-29 | Unicet | Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992018626A1 (fr) | 1991-04-17 | 1992-10-29 | Laboratoire Europeen De Biotechnologie | POLYPEPTIDES HYDROSOLUBLES AYANT UNE HAUTE AFFINITE POUR LES INTERFERONS α ET $g(b) |
| JPH0547626A (ja) | 1991-08-09 | 1993-02-26 | Canon Inc | 像投影方法及びそれを用いた半導体デバイスの製造方法 |
| WO1993004699A1 (en) | 1991-08-30 | 1993-03-18 | Genentech, Inc. | Therapeutic method for iddm |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| EP0563487A1 (en) | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5821078A (en) * | 1992-09-03 | 1998-10-13 | Yeda Research And Development Co. Ltd. | Nucleic acid encoding interferon-α/β binding protein |
| GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| CA2171955A1 (en) | 1993-09-17 | 1995-03-23 | Michael G. Tovey | Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon |
| DK0741577T3 (da) * | 1994-03-07 | 2003-02-17 | Imperial College | Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| IL118096A0 (en) | 1996-05-01 | 1996-09-12 | Yeda Res & Dev | Antibodies against interferon alpha/beta receptor |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| HK1049014A1 (zh) | 1999-07-29 | 2003-04-25 | Medarex, Inc. | 抗her2/neu的人类单克隆抗体 |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| CN1324838A (zh) * | 2000-05-24 | 2001-12-05 | 上海博德基因开发有限公司 | 一种新的多肽——人干扰素α受体19.68和编码这种多肽的多核苷酸 |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| JP2004532038A (ja) | 2001-05-17 | 2004-10-21 | ディヴァーサ コーポレイション | 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法 |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| CN1416894A (zh) * | 2001-11-09 | 2003-05-14 | 武汉春天生物工程股份有限公司 | 分泌型重组人干扰素α－2a注射液 |
| WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| DK1711207T3 (da) | 2003-12-10 | 2013-03-11 | Medarex Inc | Interferon-alpha-antistoffer og anvendelse heraf |
-
2004
- 2004-12-10 DK DK04814015.6T patent/DK1711207T3/da active
- 2004-12-10 CN CNA2004800367759A patent/CN1889978A/zh active Pending
- 2004-12-10 DK DK11183602.9T patent/DK2418220T3/da active
- 2004-12-10 KR KR1020117028318A patent/KR101225299B1/ko not_active Expired - Fee Related
- 2004-12-10 NZ NZ547157A patent/NZ547157A/xx not_active IP Right Cessation
- 2004-12-10 LT LTEP11183602.9T patent/LT2418220T/lt unknown
- 2004-12-10 ES ES11183602.9T patent/ES2641831T3/es not_active Expired - Lifetime
- 2004-12-10 PT PT111836029T patent/PT2418220T/pt unknown
- 2004-12-10 AU AU2004299833A patent/AU2004299833B2/en not_active Ceased
- 2004-12-10 IN IN2655KON2009 patent/IN2009KN02655A/en unknown
- 2004-12-10 KR KR1020067011437A patent/KR101151477B1/ko not_active Expired - Fee Related
- 2004-12-10 PT PT48140156T patent/PT1711207E/pt unknown
- 2004-12-10 JP JP2006544092A patent/JP5047626B2/ja not_active Expired - Fee Related
- 2004-12-10 US US11/009,410 patent/US7741449B2/en active Active
- 2004-12-10 PL PL11183602T patent/PL2418220T3/pl unknown
- 2004-12-10 ES ES04814015T patent/ES2399050T3/es not_active Expired - Lifetime
- 2004-12-10 SI SI200432410T patent/SI2418220T1/sl unknown
- 2004-12-10 CA CA2546054A patent/CA2546054C/en not_active Expired - Fee Related
- 2004-12-10 EP EP04814015A patent/EP1711207B1/en not_active Expired - Lifetime
- 2004-12-10 EP EP11183602.9A patent/EP2418220B1/en not_active Expired - Lifetime
- 2004-12-10 PL PL04814015T patent/PL1711207T3/pl unknown
- 2004-12-10 SI SI200431998T patent/SI1711207T1/sl unknown
- 2004-12-10 CN CN201110220119.6A patent/CN102344491B/zh not_active Expired - Fee Related
- 2004-12-10 WO PCT/US2004/041777 patent/WO2005059106A2/en not_active Ceased
- 2004-12-10 HU HUE11183602A patent/HUE035520T2/en unknown
-
2006
- 2006-05-11 IL IL175586A patent/IL175586A/en not_active IP Right Cessation
-
2009
- 2009-08-06 AU AU2009206187A patent/AU2009206187B2/en not_active Ceased
- 2009-08-31 US US12/551,250 patent/US8025882B2/en not_active Expired - Lifetime
-
2010
- 2010-11-30 JP JP2010267571A patent/JP2011097943A/ja active Pending
-
2011
- 2011-08-16 US US13/211,092 patent/US8475797B2/en not_active Expired - Fee Related
-
2013
- 2013-06-04 US US13/909,608 patent/US8722870B2/en not_active Expired - Lifetime
-
2014
- 2014-03-21 US US14/222,039 patent/US9765141B2/en not_active Expired - Fee Related
-
2017
- 2017-08-14 US US15/676,552 patent/US20170369568A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8188249B2 (en) | 2003-09-10 | 2012-05-29 | Amgen Fremont Inc. | Nucleic acid molecules encoding antibodies to M-CSF |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007513633A5 (enExample) | ||
| CN109476750B (zh) | 抗cd40抗体及其用途 | |
| CN107074943B (zh) | I型干扰素受体抗体及其用途 | |
| AU2009265808B2 (en) | Anti-human interleukin-20 antibodies | |
| KR101363120B1 (ko) | 항-인터페론 알파 모노클로날 항체 및 사용 방법 | |
| US7888484B2 (en) | Humanized antibodies to interferon alpha receptor-1 (IFNAR-1) | |
| CN110407941B (zh) | Cd39的高亲和力抗体及其用途 | |
| JP4384853B2 (ja) | 抗インターフェロンα抗体 | |
| KR20200083574A (ko) | Cd137 및 psma에 결합하는 분자 | |
| EP4192863A2 (en) | Il2rg binding molecules and methods of use | |
| JP2017195893A (ja) | 抗ｇｉｔｒ抗体 | |
| JP2006505244A5 (enExample) | ||
| PT2418220T (pt) | Anticorpos contra interferão alfa e suas utilizações | |
| TW200819464A (en) | Anti-NKG2A antibodies and uses thereof | |
| CN102603894A (zh) | 干扰素α受体1抗体及其用途 | |
| US20060088529A1 (en) | Bispecific monoclonal antibodies to IL-12 and IL-18 | |
| Chuntharapai et al. | Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE | |
| WO2022247030A1 (zh) | 抗人干扰素α受体1单克隆抗体及其应用 | |
| US20140294815A1 (en) | Caninised tumour necrosis factor antibodies and methods of using the same | |
| CN104829716A (zh) | 用于治疗疾病的抗人sema4A抗体 | |
| JP2025537810A (ja) | 減弱されたインターフェロンタンパク質および断片ならびに多機能性ポリペプチドおよびコンジュゲート | |
| CN117264054A (zh) | 靶向il-6的纳米抗体、组合物、方法及用途 | |
| NZ793343A (en) | Anti- LAG-3 antibodies and compositions | |
| RU2018120524A (ru) | Усовершенствованные агенты, связывающие tnf | |
| NZ621619B2 (en) | Caninised tumour necrosis factor antibodies and methods of using the same |